Recursion Stock Down Despite Meeting Goal in Brain Disease Study

Recursion Pharmaceuticals (RXRX) shares plunged 16.6% on Sept. 3 after announcing mixed results from a mid-stage study evaluating the safety, tolerability and efficacy of its lead candidate, REC-994, an orally bioavailable, superoxide scavenger small molecule, for symptomatic cerebral cavernous malformation (CCM) patients. Recursion's SYCAMORE Study Meets Primary Goal but Efficacy Lags Recursion reported that its phase II SYCAMORE study met the primary endpoint of safety and tolerability in CCM patients tre ...